R 0013/24 (Petition for review) of 03.12.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:R001324.20241203
- Date of decision
- 3 December 2024
- Case number
- R 0013/24
- Petition for review of
- -
- Application number
- 17175864.2
- IPC class
- A61P 7/02A61K 9/20A61K 31/4545
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- APIXABAN FORMULATIONS
- Applicant name
- Bristol-Myers Squibb Holdings Ireland Unlimited Company
Pfizer Inc. - Opponent name
- SANDOZ AG
Zentiva k.s.
Teva Pharmaceutical Industries Ltd
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Kutzenberger Wolff & Partner
von Seebach, Malte
Alfred E. Tiefenbacher (GmbH & Co. KG)
Wittkopp, Alexander
Generics (U.K.) Limited
STADA Arzneimittel AG - Board
- -
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 112a(1)European Patent Convention Art 112a(2)(c)European Patent Convention Art 112a(2)(d)European Patent Convention Art 113European Patent Convention Art 114European Patent Convention R 104European Patent Convention R 106European Patent Convention R 107European Patent Convention R 109(2)(a)Rules of procedure of the Enlarged Board of Appeal Art 13Rules of procedure of the Enlarged Board of Appeal Art 14(2)
- Keywords
- Petition for Review - clearly unallowable
Fundamental violation of Article 113(1) EPC (no) - Catchword
- -
- Cited cases
- R 0001/08R 0019/11R 0015/12R 0008/13R 0016/13R 0002/14R 0008/17T 1557/07T 1711/16T 1868/16
- Citing cases
- -
Order
For these reasons it is decided that:
The petition for review is unanimously rejected as clearly unallowable.